Publications by authors named "Denise Redding"
Article Synopsis
- * The phase III trial, IMpactMF, will compare imetelstat to the best available therapies (excluding JAK inhibitors) in these refractory MF patients.
- * The trial will administer imetelstat via IV every 21 days, focusing on overall survival as the main goal, while also examining additional effects such as symptom relief, spleen size, and safety.